Shefali Agarwal

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Cambridge, MA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Cindy Tahl, as Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Shefali Agarwal

Form 4 holding Director

FATE THERAPEUTICS INC

Security class
Stock Option (Right to Buy)
Shares / value
87,900
Estimated value
$109,200
Report date
12 Jun 2026
Price
$2.73
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Consultant and Named Executive Officer

Epizyme, Inc.

Security class
Common Stock, par value $0.0001
Shares / value
0
Estimated value
Report date
12 Aug 2022
Price
$1.41
Ownership
Direct
Form 4 holding Consultant and Named Executive Officer

Epizyme, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
0
Estimated value
Report date
09 Aug 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Gritstone bio, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
0
Estimated value
Report date
04 Apr 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Shefali Agarwal

4

Epizyme, Inc.

Report period
17 Mar 2022
Transactions
2
Transaction value
+$2,952
Accepted by SEC
21 Mar 2022, 18:05
Role
Executive Vice President, Chief Medical and Development Officer
Next action
Open filing details
4

Epizyme, Inc.

Report period
07 Feb 2022
Transactions
1
Transaction value
-$1,587
Accepted by SEC
09 Feb 2022, 16:40
Role
Executive Vice President, Chief Medical and Development Officer
Next action
Open filing details
4

Epizyme, Inc.

Report period
02 Feb 2022
Transactions
1
Transaction value
-$3,615
Accepted by SEC
04 Feb 2022, 15:15
Role
Executive Vice President, Chief Medical and Development Officer
Next action
Open filing details
4

Epizyme, Inc.

Report period
26 Jan 2022
Transactions
1
Transaction value
-$5,902
Accepted by SEC
28 Jan 2022, 15:15
Role
Executive Vice President, Chief Medical and Development Officer
Next action
Open filing details
4

Epizyme, Inc.

Report period
06 Dec 2021
Transactions
1
Transaction value
-$5,215
Accepted by SEC
07 Dec 2021, 18:03
Role
Executive Vice President, Chief Medical and Development Officer
Next action
Open filing details
4

Epizyme, Inc.

Report period
16 Aug 2021
Transactions
2
Transaction value
$0
Accepted by SEC
18 Aug 2021, 08:00
Role
Executive Vice President, Chief Medical and Development Officer
Next action
Open filing details
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .